Pulmatrix Stock Annual Yield
| PULM Stock | USD 6.12 0.01 0.16% |
Pulmatrix fundamentals help investors to digest information that contributes to Pulmatrix's financial success or failures. It also enables traders to predict the movement of Pulmatrix Stock. The fundamental analysis module provides a way to measure Pulmatrix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pulmatrix stock.
Pulmatrix | Annual Yield |
Pulmatrix Company Annual Yield Analysis
Pulmatrix's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Pulmatrix Annual Yield Driver Correlations
Understanding the fundamental principles of building solid financial models for Pulmatrix is extremely important. It helps to project a fair market value of Pulmatrix Stock properly, considering its historical fundamentals such as Annual Yield. Since Pulmatrix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pulmatrix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pulmatrix's interrelated accounts and indicators.
Click cells to compare fundamentals
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Pulmatrix has an Annual Yield of 0.0%. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Pulmatrix ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pulmatrix's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pulmatrix's managers, analysts, and investors.Environmental | Governance | Social |
Pulmatrix Fundamentals
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (0.95) % | ||||
| Operating Margin | (3.80) % | ||||
| Current Valuation | 11.57 M | ||||
| Shares Outstanding | 3.65 M | ||||
| Shares Owned By Institutions | 7.16 % | ||||
| Number Of Shares Shorted | 7.05 K | ||||
| Price To Earning | (1.30) X | ||||
| Price To Book | 2.05 X | ||||
| Price To Sales | 1.96 X | ||||
| Revenue | 7.3 M | ||||
| Gross Profit | 6.07 M | ||||
| EBITDA | (12.65 M) | ||||
| Net Income | (14.12 M) | ||||
| Cash And Equivalents | 42.91 M | ||||
| Cash Per Share | 12.67 X | ||||
| Total Debt | 8.76 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 8.19 X | ||||
| Book Value Per Share | 4.93 X | ||||
| Cash Flow From Operations | (15.98 M) | ||||
| Short Ratio | 0.75 X | ||||
| Earnings Per Share | (2.64) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 22 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 22.35 M | ||||
| Total Asset | 33.96 M | ||||
| Retained Earnings | (287.6 M) | ||||
| Working Capital | 16.93 M | ||||
| Current Asset | 8.34 M | ||||
| Current Liabilities | 4.11 M | ||||
| Net Asset | 33.96 M |
About Pulmatrix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pulmatrix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pulmatrix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pulmatrix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Pulmatrix Piotroski F Score and Pulmatrix Altman Z Score analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 3.119 | Quarterly Revenue Growth (0.16) | Return On Assets (0.30) | Return On Equity (0.59) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.